Compound ID | 2831
Synonym(s): KPI-10 | WQ-3813
Class: Fluoroquinolone
| Agent Type: | Synthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-negative & Antimycobacterial |
| Mechanism of action: | DNA synthesis inhibitor. Targets DNA gyrase |
| Target Pathogen: | Active against Mycobacterium leprae, Acinetobacter baumannii, Salmonella Typhimurium, Streptococcus penumoniae, Staphylococcus aureus, and Neisseria gonorrhoeae |
| Description: | Synthetic compound; shows similar pharmacophore to WQ-3034 with 3-isopropylaminoazetizine-1-yl at the R7 position and methyl group at the R8 position |
| Institute where first reported: | Wakunaga Pharmaceutical Co., Ltd. (Osaka, Japan); Division of Bioresources, Hokkaido University Research Center for Zoonosis Control; The Global Station for Zoonosis Control, Hokkaido University Global Institution for Collaborative Research and Education, Sapporo, Japan |
| Year first mentioned: | 2014 |
| Highest development stage: | Phase 1 |
| Development status: | Inactive |
| Reason dropped: | Undisclosed reasons (Kalidex Pharmaceuticals [Menlo Park, CA, USA] who licensed the compound for global development and commercialization rights had ceased operations in 2016) |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/11676981 |
| Guide to Pharmacology: | WQ-3810 |
| Citations: |
|